Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2012-002694-66Phase 4Completed
Phase 4, single-arm trial of fingolimod in multiple sclerosis (MS), sponsored by Sakari Simula. Primary endpoint: Change in heart rate variability and myocardial ventricular repolarisation properties. Started Oct 2012; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2012-002694-66.